Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
| ▸ | P2RY6 | Q15077 | 1/20 | 0.35 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.34 |
| ▸ | MAOB | P27338 | 13/20 | 0.34 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.32 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.32 |
| ▸ | MAOA | P21397 | 1/20 | 0.31 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL439882 | 1.00 | HSD17B10 (0.37) | HSD17B10P2RY6OPRD1MAOBTP53 | |
| SCHEMBL663119 | 1.00 | HSD17B10 (0.37) | HSD17B10P2RY6OPRD1MAOBTP53 | |
| SCHEMBL439926 | 1.00 | HSD17B10 (0.37) | HSD17B10P2RY6OPRD1MAOBTP53 | |
| SCHEMBL16607421 | 1.00 | HSD17B10 (0.37) | HSD17B10P2RY6OPRD1MAOBTP53 | |
| SCHEMBL11918176 | 0.94 | HSD17B10 (0.38) | HSD17B10P2RY6OPRD1MAOBTP53 | |
| SCHEMBL29402282 | 0.92 | HSD17B10 (0.43) | HSD17B10P2RY6OPRD1MAOBTP53 | |
| SCHEMBL1743117 | 0.92 | HSD17B10 (0.43) | HSD17B10P2RY6OPRD1MAOBTP53 | |
| SCHEMBL16925997 | 0.90 | CYP3A4 (0.36) | MAOBCYP3A4 | |
| SCHEMBL11913629 | 0.88 | HSD17B10 (0.36) | HSD17B10P2RY6OPRD1MAOBMAOA | |
| SCHEMBL6550277 | 0.87 | HSD17B10 (0.39) | HSD17B10P2RY6OPRD1MAOBTP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10556873-B2 | Bimodal ligands with macrocyclic and acyclic binding moieties, complexes and compositions thereof, and methods of using | ILLINOIS INSTITUTE OF TECHNOLOGY (US) | 2020-02-11 | — | — | US | disclosed |
| US-10189803-B2 | Synthesis of therapeutic and diagnostic drugs centered on regioselective and stereoselective ring opening of aziridinium ions | ILLINOIS INSTITUTE OF TECHNOLOGY (US) | 2019-01-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10556873-B2 | Bimodal ligands with macrocyclic and acyclic binding moieties, complexes and compositions thereof, and methods of using | UACA, CLTC, CLTA | HSD17B10 2737/4885P2RY6 4124/4885OPRD1 1548/4885 |
| US-10189803-B2 | Synthesis of therapeutic and diagnostic drugs centered on regioselective and stereoselective ring opening of aziridinium ions | AZI2, ABL1, DHPS | HSD17B10 2457/4885P2RY6 609/4885OPRD1 388/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.